⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLLS News
Cellectis S.A. American Depositary Shares
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
globenewswire.com
CLLS
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
globenewswire.com
CLLS
ALLO
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
globenewswire.com
CLLS
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
globenewswire.com
CLLS
Monthly information on share capital and company voting rights
globenewswire.com
CLLS
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
businesswire.com
PFE
AZN
UMBF
CLLS
REGN
Cellectis Announces 2026 Strategy and Catalysts
globenewswire.com
CLLS
セルトリオン、SteQeyma ™（ウステキヌマブバイオシミラー）オートインジェクターについてCHMPの承認勧告を獲得
businesswire.com
CLLS
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
globenewswire.com
ALLO
CLLS
Cellectis Announces Arbitral Decision in Dispute with Servier
globenewswire.com
CLLS